Australian startup Lumonus, known for its breakthroughs in AI-powered radiation oncology, has raised A$25 million in its latest Series B funding round. The round was led by Aviron Investment Management and backed by existing investor Oncology Ventures. The fresh investment marks a major milestone for the company, which is reshaping how cancer treatment planning and delivery happen across the globe.

Lumonus has rapidly gained traction in the healthcare sector, with its AI platform already being used across health systems in the United States, Australia, and Europe. Its growing presence in clinical care reflects a strong shift towards integrating intelligent automation into routine oncology workflows.

Proven Impact in Clinical Practice

The success of Lumonus lies in how effectively its AI tools support clinicians. So far, the platform has been used in consulting and prescribing over 280,000 cancer treatments. In addition, it has automated more than 75,000 treatment plans, reducing manual workload and ensuring greater consistency in care.

This integration of AI does not just save time. It improves accuracy and standardization, two factors critical to the success of cancer therapy. By optimizing oncology workflows, Lumonus helps healthcare providers focus more on patient outcomes and less on administrative complexity.

Focus on Growth and Innovation

The new funding will enable Lumonus to expand its footprint in the U.S. market, a region with a strong demand for next-generation healthcare technology. The company plans to enhance its two flagship products, Lumonus AI Physician and Lumonus AI Dosimetry, which are designed to streamline clinical decisions and radiation dose planning.

A significant portion of the investment will also go into advancing clinical informatics. By doing so, Lumonus aims to strengthen its partnerships with major health systems and use real-world data to improve quality measurements, operational efficiency, and the personalization of cancer care. The long-term vision is to make data-driven, AI-supported cancer treatment a global standard.

Experienced Leadership at the Core

Behind Lumonus’ success is a leadership team with over a century of combined experience in cancer research and clinical practice. Their collective expertise from top cancer centers around the world has guided the company’s mission, to empower oncology care teams and deliver high-quality, efficient, and accessible cancer treatment to patients everywhere.

With this Series B funding, Lumonus is well-positioned to strengthen its technology, scale its reach, and push forward a new era in oncology where AI and human expertise work hand in hand.